// App-Quantinova.ai

FRI0456 (2018) : Predictors for disease worsening defined by organ failure in diffuse systemic sclerosis: a european scleroderma trials and research (EUSTAR analysis

Researchers

Presenter

  • M.O. Becker

Principal Investigators

  • N. Graf

  • R. Sauter

  • Y. Allanore

  • J. Curram

  • C. Denton

  • D. Khanna

  • M. Matucci-Cerinic

  • J. Pena

  • J.E. Pope

  • O. Distler

Medical Centers

  • Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

  • graf biostatistics, Winterthur, Switzerland

  • Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

  • Paris Descartes University, Sorbonne Paris Cité, Rheumatology A Department, Cochin Hospital, Paris, France

  • Bayer Plc, Reading, UK

  • UCL Division of Medicine, Royal Free Campus, London, United Kingdom

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, United States.

  • Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

  • Bayer U.S. LLC, Whippany, NJ

  • Department of Medicine, Division of Rheumatology, University of Western Ontario, St. Joseph’s Health Care, London, ON, Canada,

Locations

  • Switzerland

  • United Kingdom

  • France

  • United States

  • Italy

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Scleroderma

  • Hypertension

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Actelion Pharmaceuticals US, Inc.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved